{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:10:11Z","timestamp":1778055011659,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1042481"],"award-info":[{"award-number":["1042481"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1093450"],"award-info":[{"award-number":["1093450"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.xphs.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T04:07:09Z","timestamp":1466222829000},"page":"2173-2179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa"],"prefix":"10.1016","volume":"105","author":[{"given":"Liang","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond S.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Nicolazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2016.05.008_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/hmg\/ddg049","article-title":"The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight","volume":"12","author":"Xu","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.xphs.2016.05.008_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ddr.20467","article-title":"The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression","volume":"72","author":"Lam","year":"2011","journal-title":"Drug Dev Res"},{"issue":"46","key":"10.1016\/j.xphs.2016.05.008_bib3","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"Beeton","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.xphs.2016.05.008_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00816.x","article-title":"The functional network of ion channels in T lymphocytes","volume":"231","author":"Cahalan","year":"2009","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.xphs.2016.05.008_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0041-0101(95)00013-C","article-title":"Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus","volume":"33","author":"Castaneda","year":"1995","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/j.xphs.2016.05.008_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.toxicon.2011.07.016","article-title":"Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases","volume":"59","author":"Chi","year":"2012","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.112.191890","article-title":"Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease","volume":"342","author":"Tarcha","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"22","key":"10.1016\/j.xphs.2016.05.008_bib8","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1016\/j.febslet.2012.09.038","article-title":"A\u00a0C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3","volume":"586","author":"Pennington","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.xphs.2016.05.008_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3280321","article-title":"A\u00a0four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom","volume":"328","author":"Lebrun","year":"1997","journal-title":"Biochem J"},{"issue":"12","key":"10.1016\/j.xphs.2016.05.008_bib10","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1110\/ps.8.12.2672","article-title":"Structural and functional consequences of the presence of a fourth disulfide bridge in the scorpion short toxins: solution structure of the potassium channel inhibitor HsTX1","volume":"8","author":"Savarin","year":"1999","journal-title":"Protein Sci"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/jp410950h","article-title":"Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3\/Kv1.1 selectivity","volume":"118","author":"Rashid","year":"2014","journal-title":"J\u00a0Phys Chem B"},{"key":"10.1016\/j.xphs.2016.05.008_bib12","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1038\/srep04509","article-title":"A\u00a0potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases","volume":"4","author":"Rashid","year":"2014","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.xphs.2016.05.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-014-1485-1","article-title":"Enhancing the buccal\u00a0mucosal delivery of peptide and protein therapeutics","volume":"32","author":"Caon","year":"2015","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2016.05.008_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibtech.2009.07.009","article-title":"Therapeutic application of peptides and proteins: parenteral forever?","volume":"27","author":"Antosova","year":"2009","journal-title":"Trends Biotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2016.05.008_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.xphs.2015.10.025","article-title":"Pulmonary delivery of the Kv1.3-blocking peptide HsTX1[R14A] for the treatment of autoimmune diseases","volume":"105","author":"Jin","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.05.008_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2011.01.027","article-title":"Advances in oral transmucosal drug delivery","volume":"153","author":"Patel","year":"2011","journal-title":"J\u00a0Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2016.05.008_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/jps.10559","article-title":"Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol","volume":"93","author":"Nicolazzo","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2005.03.022","article-title":"Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide","volume":"105","author":"Nicolazzo","year":"2005","journal-title":"J\u00a0Control Release"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.05.008_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2005.01.024","article-title":"Buccal penetration enhancers\u2014how do they really work?","volume":"105","author":"Nicolazzo","year":"2005","journal-title":"J\u00a0Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0378-5173(89)90316-5","article-title":"Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery","volume":"53","author":"Aungst","year":"1989","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2016.05.008_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejpb.2011.05.010","article-title":"Enhanced transbuccal salmon calcitonin (sCT) delivery: effect of chemical enhancers and electrical assistance on in\u00a0vitro sCT buccal permeation","volume":"79","author":"Oh","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10837459609022593","article-title":"Oramucosal delivery of LHRH: pharmacokinetic studies of controlled and enhanced transmucosal permeation","volume":"1","author":"Nakane","year":"1996","journal-title":"Pharm Dev Technol"},{"issue":"12","key":"10.1016\/j.xphs.2016.05.008_bib23","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s11095-005-7894-4","article-title":"In\u00a0vitro evaluation of various buccal permeation enhancing systems for PACAP (pituitary adenylate cyclase-activating polypeptide)","volume":"22","author":"Langoth","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2016.05.008_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2014.12.001","article-title":"Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases","volume":"199","author":"Jin","year":"2015","journal-title":"J\u00a0Control Release"},{"issue":"12","key":"10.1016\/j.xphs.2016.05.008_bib25","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/jps.10505","article-title":"The effect of various in\u00a0vitro conditions on the permeability characteristics of the buccal mucosa","volume":"92","author":"Nicolazzo","year":"2003","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2016.05.008_bib26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/mp2004127","article-title":"The involvement of a Na+- and Cl--dependent transporter in the brain uptake of amantadine and rimantadine","volume":"9","author":"Kooijmans","year":"2012","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib27","first-page":"303","article-title":"Mechanical, bioadhesive strength and biological evaluations of chitosan films for wound dressing","volume":"3","author":"Khan","year":"2000","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"20","key":"10.1016\/j.xphs.2016.05.008_bib28","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0142-9612(00)00134-4","article-title":"Enhancing effect of chitosan on peptide drug delivery across buccal mucosa","volume":"21","author":"Senel","year":"2000","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.xphs.2016.05.008_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF00226952","article-title":"Connective tissue influences on patterns of epithelial architecture and keratinization in skin and oral mucosa of the adult mouse","volume":"235","author":"Mackenzie","year":"1984","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1016\/j.xphs.2016.05.008_bib30","first-page":"31","article-title":"Differentiation in normal human buccal mucosa epithelium","volume":"128","author":"Landay","year":"1979","journal-title":"J\u00a0Anat"},{"issue":"1","key":"10.1016\/j.xphs.2016.05.008_bib31","first-page":"15","article-title":"Buccal mucosa as a route for systemic drug delivery: a review","volume":"1","author":"Shojaei","year":"1998","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2016.05.008_bib32","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1021\/bm700453x","article-title":"Chitosan as a lipid binder: a langmuir monolayer study of chitosan - lipid interactions","volume":"8","author":"Wydro","year":"2007","journal-title":"Biomacromolecules"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916414425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916414425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:20:09Z","timestamp":1773177609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916414425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0022354916414425"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.05.008","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc. on behalf of the American Pharmacists Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}